Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 18, 2018

MEI Pharma, BeiGene Will Evaluate New Combo Therapy for B-cell Cancers

News

A recent collaboration between MEI Pharma and BeiGene will test a combination of two investigational cancer therapies, ME-401 and zanubrutinib, for treating patients with B-cell cancers. Under the new partnership, MEI Pharma will amend its ongoing ... Read more

October 12, 2018

Axicabtagene Ciloleucel Gets Japan’s Orphan Drug Designation to Treat Some Non-Hodgkin’s Lymphomas

News

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug status to axicabtagene ciloleucel for the treatment of certain aggressive forms of non-Hodgkin’s lymphoma (NHL) namely diffuse large ... Read more

October 11, 2018

Beigene’s Lymphoma Treatment Zanubrutinib Shows High Response Rates in Chinese Phase 1 Trial

News

BeiGene‘s investigational zanubrutinib is showing promising response rates, ranging from 42% to 100%, in several B-cell lymphoma subtypes, preliminary data from a Chinese Phase 1 trial show. Treatment was also well-tolerated. Jun ... Read more

October 8, 2018

Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Portola Pharmaceuticals‘ investigative therapy cerdulatinib to treat patients with peripheral T-cell lymphoma (PTCL), the company announced. Orphan drug designation aims to encourage therapies for ... Read more

September 12, 2018

Corticosteroid Use May Cause Bone Side Effects in Hodgkin’s Lymphoma Patients, Study Suggests

News

Corticosteroid use is among the risk factors leading to osteonecrosis — a painful, bone-disrupting condition — in Hodgkin’s lymphoma patients, a large retrospective analysis shows. Given that no proven interventions ... Read more

August 28, 2018August 28, 2018

FDA Approves Imbruvica-Rituxan Combo Therapy for Rare Type of Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) plus Rituxan (rituximab) for the treatment of patients with a rare type of non-Hodgkin’s lymphoma called Waldenström’s macroglobulinemia (WM). This represents the first and only chemotherapy-free combination ... Read more

June 6, 2018

Phase 3 Trial to Test Yescarta as Second-line Therapy for DLBCL Patients

News

Kite Pharma has opened a new Phase 3 clinical trial to investigate the effectiveness of Yescarta (axicabtagene ciloleucel) as a second-line therapy for patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

May 29, 2018

Arzerra-Bendamustine Combo Fails to Delay Disease Worsening in Indolent Non-Hodgkin’s Lymphoma Patients in Phase 3 Trial

News

Adding Arzerra (ofatumumab) to the chemotherapy agent bendamustine did not delay disease progression or death in indolent non-Hodgkin’s lymphoma patients whose disease failed to respond to Rituxan (rituximab) treatment, according to a ... Read more

May 18, 2018May 18, 2018

1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo

News

A Phase 1b/2 clinical trial evaluating Oncternal Therapeutics‘ investigational therapy cirmtuzumab in combination with Imbruvica (ibrutinib) for the treatment of B-cell malignancies has dosed its first patient with mantle cell lymphoma. The trial is ... Read more

May 16, 2018

‘Social Network’ of Genes May Help Identify New Therapy Targets for Lymphoma, Other Cancers

News

Understanding the ‘social network’ of genes — how they interact with each other — may help scientists in both normal conditions and in diseases like cancer. Researchers developed a new ... Read more